Evidence map›Paper›PMID 32162970›Full record

Trial reportAmerican journal of respiratory and critical care medicine2020

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.

David A Lipson, Courtney Crim, Gerard J Criner, Nicola C Day, Mark T Dransfield, David M G Halpin, MeiLan K Han, C Elaine Jones, Sally Kilbride, Peter Lange and 10 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of respiratory and critical care medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06188065 (Associates of, and Time to Recovery From, Eosinopenia in Severe COPD Exacerbation), which is not on this map. Cited by 128 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 7 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06188065 recruitingnot on this mapstarted 2024, after this paper: background citation

Associates of, and Time to Recovery From, Eosinopenia in Severe COPD Exacerbation

TypeobservationalSponsorNorthumbria Healthcare NHS Foundation TrustRan2024 to 2026Enrolled200ConditionsChronic Obstructive Pulmonary DiseaseArmsBlood eosinophil count
3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 7 syntheses or guidelines pooled it, 242 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. A Proposed Checklist for Optimizing COPD Patient Discharge Processes in Italian Internal Medicine Wards.International journal of chronic obstructive pulmonary disease · 2026
    Review
  19. Review
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 4 countries.

David A LipsonClinical Sciences.ORCID 0000-0001-6732-4593
Courtney CrimClinical Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina.
Gerard J CrinerPulmonary and Critical Care Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.ORCID 0000-0003-1267-3483
Nicola C DaySafety and Medical Governance and.
Mark T DransfieldDivision of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, Alabama.
David M G HalpinUniversity of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom.ORCID 0000-0003-2009-4406
MeiLan K HanUniversity of Michigan, Pulmonary and Critical Care, Ann Arbor, Michigan.
C Elaine JonesDevelopment, R&D, and.
Sally KilbrideBiostatistics, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom.ORCID 0000-0003-0176-7273
Peter LangeSection of Epidemiology, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-0401-0081
David A LomasUCL Respiratory, University College London, London, United Kingdom.
Sally LettisBiostatistics, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom.ORCID 0000-0002-2238-8144
Pamela ManchesterGlobal Clinical Science and Delivery, GlaxoSmithKline, Collegeville, Pennsylvania.
Neil MartinGlobal Medical Affairs, GlaxoSmithKline, Brentford, Middlesex, United Kingdom.
Dawn MidwinterBiostatistics, GlaxoSmithKline, Uxbridge, Middlesex, United Kingdom.ORCID 0000-0003-2434-1152
Andrea MorrisClinical Sciences, GlaxoSmithKline, Research Triangle Park, North Carolina.
Steven J PascoeClinical Sciences.
Dave SinghCentre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
Robert A WiseDivision of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Fernando J MartinezNew York-Presbyterian Hospital/Weill Cornell Medical Center, New York, New York.
GlaxoSmithKline (United Kingdom) · GBResearch Triangle Park Foundation · USGlaxoSmithKline (United States) · USJohns Hopkins University · USManchester Academic Health Science Centre · GBNewYork–Presbyterian Hospital · USResearch & Development Establishment (Engrs.) · INTemple University · USUniversity College London · GBUniversity of Alabama at Birmingham · USUniversity of Copenhagen · DKUniversity of Exeter · GBUniversity of Leicester · GBUniversity of Michigan · USUniversity of Pennsylvania · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

MortalityAdministration, InhalationAdrenergic beta-2 Receptor AgonistsAgedAndrostadienesBenzyl AlcoholsCause of DeathChlorobenzenesDrug Therapy, CombinationFemaleForced Expiratory VolumeGlucocorticoidsHumansMaleMiddle AgedMuscarinic AntagonistsAdrenergic beta-2 Receptor AgonistsAndrostadienesBenzyl AlcoholsChlorobenzenesfluticasone furoateGlucocorticoidsGSK573719Muscarinic AntagonistsQuinuclidinesvilanterolCOPDmortalitysurvivaltriple therapy

Identifiers

PMID32162970
PMCPMC7301738
OpenAlexW3011621519

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.